Latest News and Press Releases

* Financials in line with latest expectations: - Full year revenue EUR 3.5 million, EBIT at EUR -15.8 million - Operational costs EUR 21.2 million - Liquidity of EUR 17.3 million as of...

BERLIN, Germany and SEATTLE, March 22, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF) (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, will hold its annual press...

BERLIN and SEATTLE, March 20, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company, announced that Prof. Dr. Matthias Ebert, gastroenterologist at the...

BERLIN and SEATTLE, March 5, 2007 (PRIME NEWSWIRE) -- At its meeting on March 1st, the Supervisory Board of Epigenomics AG (Frankfurt:ECX) decided to propose Heino von Prondzynski for election to the...

BERLIN and SEATTLE, Jan. 16, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) today announced that its Supervisory Board has unanimously decided to appoint Geert Walther Nygaard as the...

BERLIN, Germany, Jan. 4, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), (Other OTC:EPGNF) has entered into an R&D collaboration with Centocor Inc., a US-based, biomedicines company, to...

-- Roche Diagnostics notified Epigenomics about the termination of the joint collaboration on screening tests for early detection of cancer and returns licensed marker Septin 9 --...

-- Concordance study demonstrated excellent agreement between Epigenomics' chosen commercial diagnostic test platform and prototype research assays. -- Based on a prior FDA Early...

-- Business Fundamentals and Product Development well on Track -- Search for CEO under way - completion expected by year-end -- Cash position in line with guidance; revenue and earnings ...

-- Berlin Operations Streamlined -- Workforce Reduced by 34 Positions -- Business Strategy Unchanged -- Focus on Key Value Drivers BERLIN and SEATTLE, Oct. 26, 2006 (PRIMEZONE) -- Epigenomics...